[Blood levels of activated renin, aldosterone, catecholamine in congestive heart failure. I. Role of the adrenergic and dopaminergic systems].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Melloni.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol. and apolipoprotein A with a protective action as regards vascular atherosclerotic damage. The long-acting formula showed a greater effectiveness.
A study has been carried out on 20 male patients affected by gastric and duodenal ulcer disease and undergoing pharmacological treatment with pirenzepine, cimetidine, carbenoxolone and zolimidine in a multicentre controlled clinical trial, on PRL, TSH, FSH, LH plasma levels, taking into account the circadian rhythms of these endocrine variables. Basal and follow-up tests have been carried out, as well as a stimulation tests with TRH and LHRH. The findings do not allow for definite conclusions: two patients have shown moderate increases in the PRL levels after cimetidine; all patients have shown optimum responses to the stimulation test.
The study of hemodynamic and humoral changes stressed the possibility--statistically significant for the values of end diastolic volume (EDV), ejection fraction (EF), end systolic volume (ESV), dopamine (DA), norepinephrine (NE)-to point out the differences between normotensive and hypertensive subjects in the pre-clinic stage during exercise test, and to predict their evolution along with the relative diagnostic, therapeutic and prognostic corollaries.
Possible connections have been investigated between PVc (premature ventricular contractions) and echocardiographic patterns in 23 patients affected by MVPS. Pansystolic prolapse has been found in 12 cases and mid-systolic prolapse in 11. A correlation has been found between significant ventricular arrhythmias (50 PVc/24 h) and mid-systolic prolapse. These findings suggest the mechanical origin of cardiac rhythm disorders.
The bioavailability of non "normal-acting" and three "delayed" papaverine formulations was compared in twenty hospitalized human subjects. Papaverine was evaluated in the blood at the nanogram level by a highly sensitive, specific gas chromatographic method with electron capture detection. Only one of the three chronoid preparations had appropriately delayed bioavailability 89% in comparison to normal acting formulation.
The clinical tolerance of ibopamine hydrochloride (Sb 7505) was investigated in 12 volunteers. The drug was administered on alternate days (2nd, 4th, 6th, 8th, 10th, 12th), starting at 100 mg and increasing by 50 mg each time to reach 350 mg on the 12th day. On the other days (1st, 3rd, 5th, 7th, 9th, 11th and 13th) a placebo was given. Diuresis increased progressively with the dose, reaching a maximum increase of 88% after the last dose, and showing a small residual effect on each subsequent placebo day. Body weight showed a marginal change and decreased by 2% in the last two days of treatment. Heart rate, systolic, diastolic and mean blood pressure showed only marginal fluctuations of about 7% around the mean values, which were of little statistical and of no clinical significance. Haematological and biochemical parameters were not affected. No side effect was noticed. The dose of 350 mg may probably be increased without leading to side effects.
1 Thirty in-patients of both sexes suffering from ascitic liver cirrhosis were divided into three groups treated with (a) a placebo, (b) ibopamine (SB 7505, a new oral dopaminergic drug) and (c) frusemide, for 10 days. 2 Body weight decreased with both frusemide and ibopamine, diuresis and urinary excretion of Na+ and Cl- increased with both drugs; whereas urinary excretion of K+ increased only with frusemide. 3 An important difference between the frusemide and ibopamine treatment was encountered in creatinine clearance, which increased only with ibopamine, and in blood uric acid which increased only with frusemide. 4 The antidiuretic hormone (ADH) in the plasma of cirrhotic patients was lower than the sensitivity limit of the radioimmunoassay method, whereas in a group of healthy subjects it could be clearly measured. 5 The treatments did not affect systolic or diastolic blood pressure, heart rate, or a series of haematochemical parameters. 6 The increase in diuresis and creatinine clearance and the very good tolerability encountered with ibopamine highlight this new oral dopamine agonist as a useful drug in the management of liver cirrhosis.
Explore the source record for details and available documents.